This is a preview of subscription content, log in via an institution to check access.
Notes
This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.
References
Columbia Laboratories. Columbia Laboratories Announces European Marketing Partnership With Ardana Bioscience for Testosterone Buccal Bioadhesive Product. Media Release: 16 Oct 2002. Available from URL: http://www.businesswire.com
Drewe J, Levine H, Larsen F, Mair S. Pharmacokinetics of a new testosterone formulation, COL-1621, for hormonal replacement in males. Results of a single dose study in healthy females. 82nd Annual Meeting of the Endocrine Society: abstr. 2350, 21 Jun 2000
Columbia Laboratories Inc. Columbia Laboratories announces successful results from phase III comparative trial for testosterone buccal tablet. Media Release: [2 pages], 12 Nov 2001. Available from URL: http://www.columbialabs.com
Wang C, Kipnes M, Matsumoto A, Dobs AS, Cunningham G, et al. Novel testosterone bioadhesive buccal tablet — pharmacokinetics and safety evaluation. 84th Annual Meeting of the Endocrine Society: 471, 19 Jun 2002. Harbor-UCLA Medical Center and Research and Education Institute, Torrance, California, USA
Korbonitis M, Cullen D, Ross RRJ, Stalla G, Reincke M, et al. A comparison of Col-1621, a novel testosterone bioadhesive buccal tablet, with Androderm in hypogonadal males. 84th Annual Meeting of the Endocrine Society: 472, 19 Jun 2002. St Bartholomew’s Hospital, London, England
Columbia Laboratories Inc. Positive Data On Columbia Labs’ Testosterone Buccal Product Presented At Endocrine Society Meeting Media Release: 20 Jun 2002. Available from URL: http://www.businesswire.com
Rights and permissions
About this article
Cite this article
Testosterone-Buccal — Columbia. Drugs in R&D 4, 72–74 (2003). https://doi.org/10.2165/00126839-200304010-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200304010-00015